Clinical features and treatment outcomes of pediatric Langerhans cell histiocytosis with macrophage activation syndrome-hemophagocytic lymphohistiocytosis.

Dong WangXi-Hua ChenAng WeiChun-Ju ZhouXue ZhangHong-Hao MaHong-Yun LianLi ZhangQing ZhangXiao-Tong HuangChan-Juan WangYing YangWei LiuTian-You WangZhi-Gang LiLei CuiRui Zhang

Published in: Orphanet journal of rare diseases (2022)

LCH patients with MAS-HLH harbored specific clinical-biology characteristics compared to the multisystem LCH without MAS-HLH. The BRAF inhibitor dabrafenib provides a promising treatment option for LCH with MAS-HLH.

Keyphrases

single cell
cell therapy
stem cells
combination therapy
young adults